Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

8.395 -0.205 (-2.38%)
Delayed Quote Updated: 9:33 AM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways: 3 Key Takeaways for Long-Term Investors ↗
Its clinic network of more than 8,500 interventional psychiatry centers gives COMP360 a ready path to patients once approved. 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways (CMPS) Q3 2026 Earnings Call Transcript ↗
COMP360 targets first-half 2027 launch with $444M cash backing regulatory approval. 
Via The Motley Fool
Topics Earnings
Compass Pathways (NASDAQ:CMPS) Narrows Q3 Loss as Final NDA Submission Nears ↗
Via Chartmill
News headline image
Compass Pathways Q3 Earnings Call Highlights ↗
Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within... 
Via MarketBeat
Topics Cannabis Earnings Government
News headline image
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
From Compass Pathfinder Limited
Via Business Wire
News headline image
1 Reason Compass Pathways Is Worth a Second Look This Month ↗
An accelerated FDA review could benefit Compass Pathways. 
Via The Motley Fool
News headline image
Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Appoints Kelley Boucher as Chief People Officer
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch ↗
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances ↗
Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter,... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears ↗
Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Investor Conferences the Week of September 14th
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript ↗
COMP360 shows 39% response rate; commercial launch targeted for H1 2027. 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth... 
Via MarketBeat
Topics Government
News headline image
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
From Compass Pathfinder Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.